Martin Shkreli Debates AI Over P-Value
Martin Shkreli Debates AI Over P-Value
YouTube1 hr 44 min
Watch on YouTube
Note: AI-generated summary based on third-party content. Not financial advice. Read more.
Quick Insights

Treat SELLAS Life Sciences (SLS) as a high-risk watchlist idea, not a confirmed buy: its Phase 3 survival result for GPS is promising, but key trial details and the FDA’s approval path remain uncertain. Wait for the survival curves, analysis population, and final statistical threshold before making an investment decision; the discussion provides no validated price target or specific timeframe. Avoid treating CAPR, SAVA, or CCXI as actionable trades based on these comparisons, which provide no substantiated current thesis or price targets.

Detailed Analysis

SELLAS Life Sciences International (SLS) — Galinpepimut-S (GPS)

  • The discussion centers on SELLAS’s Phase 3 REGAL trial of GPS, an experimental cancer vaccine for certain patients with acute myeloid leukemia (AML).
  • The reported headline result was an overall-survival benefit: 24 months versus 14.7 months, a hazard ratio of 0.59, and a p-value of 0.035. One participant described this as a 41% reduction in risk of death.
  • The bullish case was that a randomized Phase 3 survival result could support a path toward FDA review. Supporters argued that a sizable effect in a relatively small trial can still produce a p-value near 0.05.
  • The skeptical case focused on information the company had not provided in the discussion: the Kaplan–Meier survival curves, the analysis population, and the final statistical threshold after interim alpha spending. The call reportedly had no Q&A.
  • Other concerns raised included the trial’s open-label design, the small number of patients and events, possible effects of censoring or post-relapse treatment, and doubts about the vaccine’s biological rationale. The transcript also notes that the company had been developing the drug for many years.
  • The transcript does not establish that the trial was manipulated or that the endpoint was missed. The speakers disagreed about how much weight to give the disclosure gaps, and some of the arguments were made while role-playing a committed shareholder.
  • A later assessment in the discussion gave a rough, explicitly non-model-based estimate of about 60% that the data would hold up under scrutiny and 25–30% for approval based on this trial alone. These were personal judgments, not verified probabilities or forecasts.

Takeaways

  • Treat the result as promising but unverified until fuller trial materials are available. In particular, investors would want to see the survival curves and numbers at risk, the analysis population, the prespecified statistical plan and final alpha boundary, and details on censoring and subsequent treatments.
  • Separate the question of whether the survival result is sound from whether it is enough for FDA approval. The discussion highlights regulatory uncertainty even if the reported result holds up.
  • The transcript offers no explicit buy or sell recommendation for SLS. It does show why relying on a company’s headline press release alone can be especially risky for a small biotech with a single prominent drug candidate.

Capricor Therapeutics (CAPR)

  • Capricor was cited as a cautionary comparison for how a positive-looking biotech result can face tougher scrutiny from the FDA.
  • The speakers described concerns about analysis choices and missing-data handling, and one speaker cited a sharp share-price decline, including a move from roughly $40 to $8. These were claims made during the discussion, not independently established here.
  • The transcript also distinguishes regulatory doubts from proof of fraud: the discussion describes Capricor’s case as evidence that a company’s positive interpretation may not satisfy regulators, while disputing the stronger allegation that the data were fraudulent.

Takeaways

  • For CAPR, the discussion points to regulatory and evidence-quality risk, not a clear investment thesis or price target.
  • As a general biotech diligence lesson, compare company claims with the FDA’s stated concerns and the underlying trial analyses. A positive endpoint or press release does not guarantee approval.

Cassava Sciences (SAVA)

  • Cassava was invoked as a historical warning about relying on company-reported clinical data. One speaker alleged that its Phase 2 data had been manipulated and referred to criminal proceedings involving a research collaborator.
  • The discussion itself corrected or disputed some details about who was involved. It does not establish that every allegation made by the speakers is accurate.

Takeaways

  • The relevant investment insight is the risk of data-integrity and credibility concerns in clinical-stage companies, especially when a thesis depends heavily on a small set of company-reported results.
  • Treat the Cassava example as a cautionary reference in the debate, not as a substantiated conclusion about SAVA’s conduct or a current recommendation.

ChemoCentryx (CCXI)

  • A speaker cited ChemoCentryx as another example of alleged problems with clinical data and regulatory disclosure. The transcript does not provide enough detail to verify that account.

Takeaways

  • The discussion supports a broad diligence point: investigate the regulatory history and public disclosures behind claims of biotech misconduct rather than treating an analogy as proof about another company.
  • No current investment view or price target for CCXI was given.

NVIDIA (NVDA)

  • NVIDIA was mentioned only in a brief exchange about a request for access to Godel Terminal. No investment outlook, valuation, or business analysis was provided.

Takeaways

  • The transcript gives no actionable investment thesis for NVDA.

CL1 — Crude-Oil Reference Unclear

  • The transcript asks why someone was bullish on “CL1” and mentions Venezuela and additional pipelines as possible supply factors.
  • The ticker/reference is not explained clearly. If it refers to a crude-oil futures contract, the comments suggest that supply developments could be relevant, but no specific price outlook or timeline is provided.

Takeaways

  • Do not treat this as a defined oil-market forecast: the instrument and the speaker’s reasoning are unclear.
  • The transcript provides no price target or explicit trade recommendation.

Pfizer (PFE), Reddit (RDDT) and Morgan Stanley (MS)

  • Pfizer was mentioned as a contrast between a large pharmaceutical company with a broad drug pipeline and a biotech focused on one drug. No assessment of Pfizer’s stock was offered.
  • Reddit and Morgan Stanley were mentioned jokingly in an exchange about buying an investment because Reddit recommended it. No substantive analysis of either company was given.

Takeaways

  • These references do not amount to investment recommendations or meaningful stock analysis.
  • The broader point from the discussion is to avoid substituting social-media enthusiasm or a company’s own messaging for independent evaluation of clinical evidence.
Ask about this postAnswers are grounded in this post's content.
Video Description
Sign Up For Godel Terminal: https://app.godelterminal.com/?via=shkreliplanet Use Promo Code: Shkreliplanet For 30% Off The First Month Follow Martin Shkreli On Twitter: https://twitter.com/MartinShkreli Follow Martin Shkreli On Instagram: https://www.instagram.com/martinshkreli15/ Trade on Interactive Brokers: https://tinyurl.com/ye2aj6uz Book Recommendation About Stocks & Investing: Common Stocks and Uncommon Profits By Phil Fisher: https://amzn.to/3MCip3R The Intelligent Investor By Benjamin Graham: https://amzn.to/3Xn7jnY One Up On Wall Street By Peter Lynch: https://amzn.to/3XlrfYx
About Shkreli Planet
Shkreli Planet

Shkreli Planet

By @shkreliplanet